Literature DB >> 20685233

Of mice and men: human RNA polymerase III promoter U6 is more efficient than its murine homologue for shRNA expression from a lentiviral vector in both human and murine progenitor cells.

Roland Roelz1, Ingo H Pilz, Manuel Mutschler, Heike L Pahl.   

Abstract

OBJECTIVE: RNA interference mediated by transcription of short hairpin RNAs (shRNAs) from lentiviral expression vectors has emerged as an efficient method to effectively and specifically silence gene expression in a vast variety of mammalian cells. shRNA expression is routinely driven by a RNA polymerase III promoter, most often by the U6 promoter. Here we demonstrate that U6 promoter activity-and consequently gene silencing success-differs significantly among species.
MATERIALS AND METHODS: We have modified pLeGO-G, an HIV-based third-generation lentivector, to express a 19nt shRNA sequence against the human transcription factor nuclear factor erythroid 2 or against its murine homologue, as well as an shRNA against murine JAK2, from either the human or the murine U6 promoter. Gene silencing efficiency was analyzed in a human erythroleukemic cell line, in primary human CD34(+) cells, as well as in a murine erythroleukemic cell line and in primary murine bone marrow.
RESULTS: ShRNA expression from the human U6 promoter resulted in a fourfold increase in knockdown efficiency compared to expression from the murine U6 promoter in both human and murine cells.
CONCLUSIONS: The U6 promoter constitutes an important determinant for efficient gene silencing by shRNAs.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20685233     DOI: 10.1016/j.exphem.2010.05.005

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  24 in total

1.  Human U6 promoter drives stronger shRNA activity than its schistosome orthologue in Schistosoma mansoni and human fibrosarcoma cells.

Authors:  Raphaël Duvoisin; Mary A Ayuk; Gabriel Rinaldi; Sutas Suttiprapa; Victoria H Mann; Clarence M Lee; Nicola Harris; Paul J Brindley
Journal:  Transgenic Res       Date:  2011-09-28       Impact factor: 2.788

2.  Necessity for Validation of Effectiveness of Selected Guide RNA In Silico for Application of CRISPR/Cas9.

Authors:  Dong-Hwan Kim; Joonbum Lee; Yeunsu Suh; Kichoon Lee
Journal:  Mol Biotechnol       Date:  2021-01-02       Impact factor: 2.695

3.  Dodging silver bullets: good CRISPR gene-drive design is critical for eradicating exotic vertebrates.

Authors:  Thomas A A Prowse; Phillip Cassey; Joshua V Ross; Chandran Pfitzner; Talia A Wittmann; Paul Thomas
Journal:  Proc Biol Sci       Date:  2017-08-16       Impact factor: 5.349

4.  NFE2 regulates transcription of multiple enzymes in the heme biosynthesis pathway.

Authors:  Lara Rheinemann; Thalia S Seeger; Julius Wehrle; Heike L Pahl
Journal:  Haematologica       Date:  2014-06-20       Impact factor: 9.941

5.  A novel role for nuclear factor-erythroid 2 in erythroid maturation by modulation of mitochondrial autophagy.

Authors:  Monika Gothwal; Julius Wehrle; Konrad Aumann; Vanessa Zimmermann; Albert Gründer; Heike L Pahl
Journal:  Haematologica       Date:  2016-06-16       Impact factor: 9.941

Review 6.  Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both.

Authors:  S Koschmieder; T I Mughal; H C Hasselbalch; G Barosi; P Valent; J-J Kiladjian; G Jeryczynski; H Gisslinger; J S Jutzi; H L Pahl; R Hehlmann; A Maria Vannucchi; F Cervantes; R T Silver; T Barbui
Journal:  Leukemia       Date:  2016-02-08       Impact factor: 11.528

7.  Altered NFE2 activity predisposes to leukemic transformation and myelosarcoma with AML-specific aberrations.

Authors:  Jonas Samuel Jutzi; Titiksha Basu; Maximilian Pellmann; Sandra Kaiser; Doris Steinemann; Mathijs A Sanders; Adil S A Hinai; Annelieke Zeilemaker; Sarolta Bojtine Kovacs; Christoph Koellerer; Jenny Ostendorp; Konrad Aumann; Wei Wang; Emmanuel Raffoux; Bruno Cassinat; Lars Bullinger; Brigitte Schlegelberger; Peter J M Valk; Heike Luise Pahl
Journal:  Blood       Date:  2019-02-12       Impact factor: 22.113

8.  Transcription factor nuclear factor erythroid-2 mediates expression of the cytokine interleukin 8, a known predictor of inferior outcome in patients with myeloproliferative neoplasms.

Authors:  Julius Wehrle; Thalia S Seeger; Sven Schwemmers; Dietmar Pfeifer; Alla Bulashevska; Heike L Pahl
Journal:  Haematologica       Date:  2013-02-26       Impact factor: 9.941

9.  Subcellular mislocalization of the transcription factor NF-E2 in erythroid cells discriminates prefibrotic primary myelofibrosis from essential thrombocythemia.

Authors:  Konrad Aumann; Anna-Verena Frey; Annette M May; Dieter Hauschke; Clemens Kreutz; Jan P Marx; Jens Timmer; Martin Werner; Heike L Pahl
Journal:  Blood       Date:  2013-05-13       Impact factor: 22.113

10.  Elevated nuclear factor erythroid-2 levels promote epo-independent erythroid maturation and recapitulate the hematopoietic stem cell and common myeloid progenitor expansion observed in polycythemia vera patients.

Authors:  Ruzhica Bogeska; Heike L Pahl
Journal:  Stem Cells Transl Med       Date:  2013-01-22       Impact factor: 6.940

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.